iOmx Therapeutics AG Alternatives & Competitors
12 companies similar to iOmx Therapeutics AG — Developing next-generation targeted cancer immunotherapy treatments
Companies similar to iOmx Therapeutics AG
Glycyx
Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance...
San Francisco, United Sta...
Prelude Therapeutics
Precision Oncology, Redefined.
Wilmington, United States
Sumitomo Pharma Oncology
is part of Sumitomo Pharma America as of July 2023
Cambridge, United States
ORIC Pharmaceuticals Inc.
Overcoming Resistance In Cancer
South San Francisco, Unit...
Rival Readout
Competing with iOmx Therapeutics AG? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
7 Hills Pharma
First-in-concept platform of oral drugs to overcome immunotherapy resistance
Houston, United States
NEOGAP Therapeutics AB
Science for cure.
Stockholm, Sweden
FineImmu
Creating future health with advanced cell therapy drugs and precision immunodiagnostic pro...
London, United Kingdom
Outpace Bio
Revolutionizing Cell Therapy with Protein Design
Seattle, United States
ESPERANCE PHARMACEUTICALS, INC.
Pioneering a new era of anticancer treatment with drugs that precisely target and eliminat...
Tollys
A new dimension in immuno-oncology
Lyon, France
About iOmx Therapeutics AG
iOmx Therapeutics AG is positioned at the forefront of the immuno-oncology sector, striving to revolutionize cancer treatment with its next-generation targeted cancer immunotherapy solutions. Founded in 2016 and headquartered in Germany, iOmx utilizes its robust technology platform to advance a portfolio of early-stage...
Development of targeted cancer immunotherapy treatments, Translating immune evasion biology into drug programs, Innovative drug pipeline, Novel immune checkpoint target identification
Cancer patients, Healthcare providers, Oncologists, Pharmaceutical companies, Biotech investors
Immuno-oncology, Targeted Cancer Therapy, Immune Checkpoint Modulators, Drug Development, Pre-clinical Development, Clinical Development, Tumor Immunology, Checkpoint Inhibitors, Tumor Cell Screening, Immune Resistance Mechanisms, Novel Target Identification, Immune Response Reactivation, Biotechnology Start-up, Therapeutic Portfolio
B2B, B2B2C
Licensing, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around iOmx Therapeutics AG: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at iOmx Therapeutics AG on 28 May 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
